Flow & Fundamentals (@FlowFundamental) profile picture

My opinions are my own and are not a recommendation to buy or sell any security. I share my DD in securities that I’m long.

Joined March 2021
Photo by Flow & Fundamentals (@FlowFundamental)Photo by Flow & Fundamentals (@FlowFundamental)Photo by Flow & Fundamentals (@FlowFundamental)
$AVR DurAVR 1-year preview Technical success rose 43/50→50/50 as the valve and delivery system evolved. Mean STS 4.7%, 61% NYHA III/IV, 9 type 1 bicuspids. 2 disabling strokes by day 30 in 100. One later in the prior 65. Watching gradients, EOA and new strokes/CV admissions.
3
9
820
$AVR Paradigm Powered Secondary Review 10) Moderate/severe PPM vs Evolut- Noninferiority My base case is ~3% moderate/severe PPM for DurAVR vs ~8% for Evolut at 1 year, supporting noninferiority with a potential numerical advantage. Cross-study model assuming 47% small/53% med.
6
473
$AVR Paradigm Powered Secondary Review 9) Effective orifice area vs Evolut- Superiority My conservative base case is ~0.05–0.10 cm² larger EOA with DurAVR at 1 year. Modeled using comparable CT annulus-area bands, assuming 47% small/53% medium and no large valves.
1
9
660
Medium-valve performance drives the projected advantage. This is the most narrow secondary modeled. Thesis only requires matching Evolut hemodynamics.
2
92
I learned I have ADHD today 😂
BREAKING: Cognitive researchers confirm that leaving half-drunk mugs of coffee, water glasses, and soda cans scattered across every room in the house isn't "sloppiness"—it is a documented visual processing quirk called "Salience Habituation." If you live with someone who leaves a trail of 6 abandoned drinks behind them every day, here is what is actually happening inside their brain: 1/5
60
$AVR Paradigm Powered Secondary Review 8) LV mass index regression vs Sapien- Superiority The most difficult to model. DurAVR showed rapid LV mass regression (~18%) at 6 months—broadly comparable in magnitude to older-generation SAPIEN results at 1 year.
1
6
434
Different populations and measurements limit direct comparison; superiority remains unproven. References: Garg et al. EHJ–Valvular and Structural Heart Disease, 2026. doi:10.1093/ehjvshd/xwag011 Chau et al. JACC, 2020. doi:10.1016/j.jacc.2020.03.042
84
$AVR Paradigm Powered Secondary Review 7) Indexed aortic flow reversal ratio vs Sapien- Superiority My base case favors DurAVR, with indexed flow reversal ~2.5–2.6 %/cm² at 1 year if its 6-month performance holds. Early paired MRI data showed ~33% improvement from baseline.
1
5
439
The advantage over Ultra RESILIA remains unquantified.
100
REBOOT-PARADOX. No significant survival difference does not establish no benefit. Among survivors, symptom improvement and HF rehospitalization favored immediate TAVR. For $AVR, the question is whether DurAVR’s physiologic flow translates into better outcomes.
Does early TAVR improve survival in symptomatic paradoxical low-flow, low-gradient aortic stenosis? REBOOT-PARADOX (n=120): death 29% vs 37% on medical therapy (P=.60). Symptoms and readmissions favored TAVR; trial stopped early. @JuMehilli New in #JACC: bit.ly/4zMzVK3
1
5
673
LFLG aortic stenosis are among the sickest patients. Notice the heart remodels over several years leading to improved outcomes. $AVR has shown rapid LV mass regression following durAVR placement in EFS; Garg P, et al Eur Heart J Valv Struct Heart Dis. 2026;2(1). Flow matters.
1
3
244
$AVR Paradigm Powered Secondary Review 6) Mean aortic valve gradient in patients under 75 vs Sapien- Superiority My base case for DurAVR’s mean gradient at 1 year in patients under 75 comes in ~2 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
2
8
735
Extrapolated from the small/medium-annulus model. That’s 6/6 modeled secondary superior wins.
1
1
134
$AVR $AVR Paradigm Powered Secondary Review 5) Mean aortic valve gradient in women vs Sapien- Superiority My base case for DurAVR’s mean gradient in women at 1 year comes in ~2 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
1
9
713
The assumed advantage is 2.4 mmHg in small annuli and 2.0 mmHg in medium annuli. Any mix of those two groups produces an estimated difference between 2.0 and 2.4 mmHg. DurAVR’s 100-patient small-annulus cohort was 78% female. SMART trial was 86.7% female.
4
116
Key companies covered in the market analysis include Abbott Laboratories; Medtronic Plc.; Artivion Inc.; Boston Scientific Corp.; Edwards Lifesciences Corp.; JenaValve Technology, Inc.; Blue Sail Medical Co Ltd.; JC Medical, Inc.; Venus Medtech Hangzhou Inc.; Anteris Technologies
153
$AVR Paradigm Powered Secondary Review 4) Mean aortic valve gradient in small annuli vs Sapien- Superiority My base case for DurAVR’s mean gradient at 1 year in annuli <430 mm² comes in ~2.5 mmHg below SAPIEN, assuming 100% Ultra RESILIA controls.
1
9
663
Cross-study estimate using available data; randomized confirmation pending. The first four secondaries we are modeling comfortable wins using conservative assumptions.
2
105